Breaks Categories: News

WednesdayJan 04, 2017 12:28 pm

NetworkNewsBreaks – Concordia International Corp.’s (NASDAQ: CXRX) Shares Buoyed by Agreement with RedHill Biopharma Ltd. (NASDAQ: RDHL)

Concordia International (NASDAQ: CXRX) is trading nearly 4% higher a day after the pharmaceutical company announced its three-year, co-promotion agreement with RedHill Biopharma Ltd. (NASDAQ: RDHL) to expand sales of Donnatal®, Concordia's product used in the treatment of irritable bowel syndrome. Per the agreement, RedHill will aim to increase the promotion of Donnatal® among U.S. doctors who treat irritable bowel syndrome. Additionally, RedHill will incur the sales and marketing costs while Concordia will provide materials and samples. Marketing efforts are anticipated to begin during the current quarter. "This agreement is a cost-effective approach to promoting Donnatal® in a manner consistent…

Continue Reading

WednesdayJan 04, 2017 12:15 pm

NetworkNewsBreaks – Evoke Pharma, Inc. (NASDAQ: EVOK) Shares Surge on Positive Data from Phase 3 Gimoti Study

Shares of Evoke Pharma (NASDAQ: EVOK) are 35% higher in morning trade after the company reported positive data from its phase 3 trial of Gimoti for symptomatic relief of acute and recurrent diabetic gastroparesis. While the study failed to reach its primary endpoint, Gimoti “significantly” reduced nausea and abdominal pain in moderate to severe patients. Evoke notes that the results are consistent with FDA guidance on the clinical evaluation of drugs used to treat gastroparesis. “As our discussions with the FDA progressed over the past few months, we have continued to analyze data from our Phase 3 trial of Gimoti…

Continue Reading

FridayDec 30, 2016 12:39 pm

NetworkNewsBreaks – SuperCom (NASDAQ: SPCB) Secures $9M Contract with Large South American Country; Commences Project Today

SuperCom (NASDAQ: SPCB) this morning announced that, together with its local partner, the company has been awarded a $9 million contract by a large South American government customer to migrate and implement SuperCom's proprietary secured web-based Land and Geographical Registration and Information Management System nationwide. Project commencement is expected today and completion is anticipated by July 2018. SuperCom said it expects to achieve the majority of the contract value in 2017. "We, together with our local partner, have been given an opportunity to deploy our technology as part of a meaningful government process and gain trust while building a new…

Continue Reading

WednesdayDec 28, 2016 12:33 pm

NetworkNewsBreaks – Ecoark Holdings, Inc. (EARK) Offers Pallet-Level Quality Management with Zest Labs Solutions

According to the Food and Agriculture Organization's (FAO) “Global Food Losses and Food Waste” report, there is still over 30% of post-harvest waste between the farm, retail and consumer, which is why Ecoark Holdings, Inc. (OTCQX: EARK) - through its subsidiary Zest Labs - offers mobile and office-based solutions to help with pallet-level quality management from harvest to store. Whether it’s in the field or from the office, companies using the Zest Labs solutions are now able to view every operational action of their business in real-time. The solutions include pallet-level time and temperature tracking, pre-cool prioritization and monitoring, the…

Continue Reading

TuesdayDec 27, 2016 11:36 am

NetworkNewsBreaks – DryShips, Inc. (NASDAQ: DRYS) Enters Into $200M Stock Purchase Agreement, Plans to Boost Fleet and Earnings Capacity

DryShips (NASDAQ: DRYS) this morning said it has entered into an agreement with Kalani Investments Limited, an entity organized in the British Virgin Islands, allowing the company to sell up to $200 million of its common stock to Kalani over a 24-month period. DryShips has also agreed to issue up to $1.5 million of its common stock to Kalani as a commitment fee. "We are very excited to now have the ability to raise up to $200 million of equity having full control of the timing. Together with available liquidity in excess of $120 million we are now in a…

Continue Reading

FridayDec 23, 2016 1:14 pm

NetworkNewsBreaks – Neothetics (NASDAQ: NEOT) Initiates Phase 2 Trial of Fat Reduction Drug; Shares Higher

Neothetics (NASDAQ: NEOT) says it has commenced the phase 2 proof of concept trial for its fat reduction candidate, LIPO-202. Study endpoints include both safety and efficacy measurements, and the company expects to report top-line data in late second quarter 2017. “The initiation of our Phase 2 proof of concept trial for LIPO-202 for the reduction of submental fat is a significant milestone for Neothetics … We continue to believe LIPO-202 could have exceptional impact in the submental fat reduction market,” Neothetics’ operating committee and board of directors member Kim Kamdar, Ph.D. stated in the news release. To view the…

Continue Reading

ThursdayDec 22, 2016 3:10 pm

NetworkNewsBreaks – Investors Applauding Akebia’s (NASDAQ: AKBA) Recent Alliance with Otsuka Pharmaceutical (OTSKF)

Shares of Akebia Therapeutics (NASDAQ: AKBA) are ticking higher in mid-day trade, following handsome gains on Tuesday after the company announced its collaboration and license agreement with Otsuka Pharmaceutical (OTC: OTSKF) for vadadustat in the U.S. The companies will equally share the revenue and commercialization costs of vadadusta for the treatment of anemia associated with chronic kidney disease. “Our alliance with Otsuka, one of the world’s innovative pharmaceutical leaders, also allows us to prepare an optimal launch of vadadustat, as we will equally share commercial responsibility. Otsuka brings a well-established commercial presence and infrastructure in the U.S., and we share…

Continue Reading

ThursdayDec 22, 2016 1:47 pm

NetworkNewsBreaks – Inovio (NASDAQ: INO) Releases Early Clinical Results of Zika Vaccine

Inovio Pharmaceuticals (NASDAQ: INO) released results of its DNA-based Zika vaccine (GLS-5700) phase I trial designed to evaluate the safety, tolerability and induction and persistence of Zika specific antibody and T cell responses. In initial testing, Zika-naïve subjects in both low dose and high dose vaccine groups demonstrated Zika antigen-specific antibody responses after one or two vaccinations. The vaccine has been well tolerated and no significant safety concerns have been noted to date. “These early clinical results show that Inovio is on track to rapidly develop Zika countermeasures for this disease that has no currently existing vaccine or treatment. Our…

Continue Reading

ThursdayDec 22, 2016 12:49 pm

NetworkNewsBreaks – Tokai Pharmaceuticals (NASDAQ: TKAI) Trades Higher on Share Purchase Agreement with Otic Pharma

Tokai Pharmaceuticals (NASDAQ: TKAI) shares are up 38% mid-day after the company announced its definitive share purchase agreement with Otic Pharma Ltd., as well as the shareholders of Otic Pharma who will become the majority owners of Tokai. The transaction will result in a NASDAQ-listed company focused on the development and commercialization of products for ear, nose and throat (ENT) disorders. The emerging company will operate under the name OticPharma, Inc., and will be led by current Otic Pharma CEO Gregory J. Flesher. “Over the last several months, Tokai has conducted an extensive review of strategic alternatives aimed at maximizing…

Continue Reading

TuesdayDec 20, 2016 1:34 pm

NetworkNewsBreaks – BioLife Solutions, Inc. (NASDAQ: BLFS) Inks Multi-Year Supply Agreement with TissueGene for CryoStor® Use in Invossa™

BioLife Solutions (NASDAQ: BLFS) is trading higher after announcing its 10-year supply agreement with TissueGene, a developer of regenerative therapies for the treatment of various orthopedic diseases. BioLife's CryoStor clinical grade cell freeze media is integrated into TissueGene's manufacturing process for Invossa, a drug designed to treat osteoarthritis of the knee through a single intra-articular injection. "We are very pleased to support TissueGene and Kolon with this long term supply agreement, which further supports our growth potential of the franchise we have built in the high growth cell therapy industry.  We believe that CryoStor and HypoThermosol are incorporated into more…

Continue Reading